Sugi Predict

Sugi Predict / Compounds / SCHEMBL21528028

SCHEMBL21528028

SCHEMBL21528028

O=C(O)NCCOCCOCCN1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ KDM4E B2RXH2 7/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.42
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ SIGMAR1 Q99720 2/20 0.38
▸ GAA P10253 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21070088 0.98 MEN1 (0.52) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL26726296 0.82 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL26726301 0.82 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL25815852 0.82 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL25816571 0.82 MEN1 (0.50) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL14861110 0.82 HSD17B10 (0.49) MEN1KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL165764 0.81 HSD17B10 (0.61) MEN1KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL3954077 0.80 HSD17B10 (0.47) MEN1KMT2AKDM4EALDH1A1HSD17B10
SCHEMBL26923862 0.79 HRH3 (0.41) MEN1KMT2AKDM4EALDH1A1TDP1
SCHEMBL22124598 0.79 SMN1; SMN2 (0.62) MEN1KMT2AKDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-05-23 — — US disclosed
EP-4234031-A2 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2023-08-30 — — EP disclosed
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2023-06-27 — — US disclosed
EP-4168002-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS Revolution Medicines, Inc. (US) 2023-04-26 — — EP disclosed
EP-3788049-B1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2023-03-29 — — EP disclosed
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-02-23 — — US disclosed
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2022-06-21 — — US disclosed
WO-2021257736-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS Revolution Medicines, Inc. (US) 2021-12-23 — — WO disclosed
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-11-04 — — US disclosed
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2021-04-20 — — US disclosed
EP-3788049-A1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2021-03-10 — — EP disclosed
EP-3788050-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2021-03-10 — — EP disclosed
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Revolution Medicines, Inc. 2019-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR MEN1 744/4885KMT2A 2883/4885KDM4E 1155/4885
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR MEN1 369/4885KMT2A 3334/4885KDM4E 1313/4885
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR MEN1 369/4885KMT2A 3334/4885KDM4E 1313/4885
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR MEN1 369/4885KMT2A 3334/4885KDM4E 1313/4885
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR MEN1 744/4885KMT2A 2883/4885KDM4E 1155/4885
US-20230233569-A1 METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS KRAS, HRAS, MTOR MEN1 2520/4885KMT2A 3021/4885KDM4E 2157/4885
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR MEN1 369/4885KMT2A 3334/4885KDM4E 1313/4885
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR MEN1 369/4885KMT2A 3334/4885KDM4E 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.